{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-035082","form_type":"8-K","ticker":"ANVS","cik":"0001477845","company_name":"Annovis Bio, Inc.","filed_at":"2024-03-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.288468+00:00","generated_at":"2026-06-04T17:02:42.115501+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Annovis Bio enters securities purchase agreement for $1.025M common stock offering","bullets":["Sold 114,911 shares at $8.92/share to institutional investor for gross proceeds of $1,025,000.","Issued under effective shelf registration statement on Form S-3 (333-276814) effective Feb 12, 2024.","Closing expected promptly after conditions satisfied, including NYSE listing of the shares.","30-day lock-up restricts additional equity issuances, warrant amendments, and variable rate transactions."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-035082","json":"https://secwatch.observer/filing/0001104659-24-035082.json","markdown":"https://secwatch.observer/filing/0001104659-24-035082.md","text":"https://secwatch.observer/filing/0001104659-24-035082.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1477845/000110465924035082/0001104659-24-035082-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1477845/000110465924035082/tm248952d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T17:02:42.115501+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1f6acea34e54f10530084e7cc2f840092d5e7f8d","claim":"Annovis Bio, Inc. entered into Securities Purchase Agreement with an institutional investor valued at aggregate gross proceeds of $1,025,000 (effective 2024-03-15).","evidence_excerpt":"On March 15, 2024, Annovis Bio, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with an institutional investor (the “Buyer”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1477845/000110465924035082/0001104659-24-035082-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"an institutional investor"},{"label":"Value","value":"aggregate gross proceeds of $1,025,000"},{"label":"Effective","value":"2024-03-15"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}